Moreau, P.

patient myeloma thalidomide dexamethasone lenalidomide therapy treatment response study regimen combination month group neutropenia bortezomib university survival blood trial factor cancer hospital grade table phase disease chemotherapy melphalan palumbo serum effect result leukemia high-dose dexamethasone neuropathy prednisone event criteria randomized reduction high-dose hematology department doxorubicin guideline g-csf response rate agent infection outcome oncol institute recommendation diagnosis level signi cyclophosphamide marrow cell transplantation signi ficantly progression ef ficacy center group guidelines myeloma patients management meeting abstracts transplantation mayo clinic pegylated liposomal doxorubicin stage clinic celgene number 100 ml risk factors richardson myeloma sk kumar erasmus mc france